Metastatic HER2-Negative Gastroesophageal Adenocarcinoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Metastatic HER2-Negative Gastroesophageal Adenocarcinoma Emerging Therapy and TPP Insights

Thelansis’s “Metastatic HER2-Negative Gastroesophageal Adenocarcinoma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Metastatic HER2-Negative Gastroesophageal Adenocarcinoma Overview

Metastatic HER2-negative gastroesophageal adenocarcinoma includes cancers of the stomach, gastroesophageal junction (GEJ), or esophagus that have spread. Symptoms may include dysphagia, early satiety, abdominal discomfort, bleeding, anemia, or weight loss. Treatment depends on patient fitness and biomarkers, including PD-L1, mismatch-repair/microsatellite-instability status, and CLDN18.2. Fluoropyrimidine–platinum chemotherapy is a common backbone. For pMMR/MSS disease with PD-L1 expression, adding a PD-1 inhibitor may be appropriate; for CLDN18.2-positive gastric/GEJ tumors, zolbetuximab plus chemotherapy is an option. If both biomarkers are positive, treatment is individualized; MSI-H/dMMR tumors may benefit from immunotherapy-based regimens. When no actionable biomarker is present, chemotherapy remains appropriate. Despite expanded options, responses vary and resistance remains a challenge, making biomarker testing and supportive care integral to treatment.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)